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Abstract: A series of novel mono-1,2,3-triazole and bis-1,2,3-triazole acyclonucleoside 
analogues of 9-(4-hydroxybutyl)guanine was prepared via copper(I)-catalyzed 1,3-dipolar 
cycloaddition of N-9 propargylpurine, N-1-propargylpyrimidines/as-triazine with the 
azido-pseudo-sugar 4-azidobutylacetate under solvent-free microwave conditions, followed 
by treatment with K2CO3/MeOH, or NH3/MeOH. All compounds studied in this work were 
screened for their antiviral activities [against human rhinovirus (HRV) and hepatitis C virus 
(HCV)] and antibacterial activities against a series of Gram positive and negative bacteria. 
Keywords: 1,3-dipolar cycloaddition; 1,2,3 triazole; 1,2,3-bis-triazoles; click azide-alkyne; 
microwave-assisted synthesis; antibacterial activities 
 
1. Introduction 
For several years, there has been an intensive search for drugs effective in chemotherapy of viral 
diseases like AIDS, herpes simplex, Hepatitis C and cytomegaloviruses [1-5]. Most of these drugs are 
analogues of naturally occurring nucleosides [6]. A series of nucleoside analogues were synthesised in 
which the cyclic carbohydrate moiety was replaced by an acyclic side chain [7-12]. The biological 
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activities of acyclonucleosides, after the discovery of acyclovir [9-((2-hydroxyethoxy) methyl)guanine 
ACV (Zovirax)] (1, Figure 1), have led to the synthesis of a diversity of structures. Many variations 
were tested in order to enhance biological activity and selectivity, or to lower toxicity [13-18]. Among 
them HBG [9-(4-hydroxybutyl)guanine] (2, Figure 1) presented good activity against HSV-1 and HSV-2. 
Figure 1. Examples of drugs effective in chemotherapy. 
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On the other hand, for antiviral agents, triazolonucleosides and acyclonucleosides have attracted 
much attention. Ribavirin (3, Figure 1), whose nucleobase consists of an unnatural triazole moiety, was 
the first synthetic nucleoside to show a broad spectrum of antiviral activities against many RNA and 
DNA viruses [19]. Furthermore, nucleosides with unnatural triazole nucleobases are generally resistant 
to nucleos(t)ide metabolizing enzymes, and this may lead to better in vivo stability and efficiency. 
Because of their broad application as pharmaceuticals like antibacterial or antiviral agents, a great 
number of 1,2,3-triazole derivatives have been reported as potent antiviral, antimicrobial or 
antiproliferative  agents [20]. Also the synthesis and biological evaluation of carbonucleosides 
(substances in which the anomeric oxygen of the furanose ring is replaced by a methylene group), 
having a 1,2,3-triazole ring as a nucleobase (e.g., 4, Figure 1) have been reported. Until now, very few 
efforts were made on appending aromatic systems to triazole nucleosides. We expect that these 
extended aromatic systems may offer advantageous binding properties to the corresponding biological 
targets via larger aromatic systems. 
2. Results and Discussion 
Different synthetic methods have been developed for the construction of triazole frameworks. These 
compounds are typically prepared by thermal cycloaddition of azides and alkynes [21,22]. Two 
problems are, however, encountered in this transformation: (1) reactivity of the substrates, either 
alkynes or azides require activation by an electron withdrawing group, otherwise, the reaction must be 
carried out at higher temperatures; (2) the regioselectivity of the products, as for unsymmetrical 
alkynes, a mixture of regioisomers is obtained in most cases. Since Sharpless reported copper(I) Molecules 2012, 17                  
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catalysis for regioselective cycloaddition of terminal alkynes and azides to yield exclusively   
1,4-disubstituted-1,2,3-triazoles, many groups have reported their results employing different kinds of Cu(I) 
salts as catalyst [23-35]. In addition, microwave irradiation has become a powerful synthetic tool for 
rapid synthesis of a variety of biologically active compounds. Its use to is to enhance the rates of 
classical organic reactions. 
In the light of these findings and in continuation of our previous investigation [34], we considered 
the synthesis of new 1,2,3-triazole and bis-1,2,3-triazole acyclonucleosides. They carry either a purine, 
pyrimidine or as-triazine moiety as nucleobase appended to 1,2,3-triazole. They can be regarded as 
analogues of 9-(4-hydroxybutyl)guanine (HBG). We went further to combine nucleobase and triazole 
rings with an acyclic side-chain developed bistriazolyl acyclonucleosides, and determined their in vitro 
antiviral and antibacterial activities. 
2.1. Chemistry 
The starting material 4-azidobutylacetate (7) was prepared according to the literature [34,36] from 
4-bromobutylacetate (6) and sodium azide at 90–95 °C for 4 h (Scheme 1). 
Scheme 1. Synthesis of the azidobutylacetate 7 from bromobutylacetate 6. 
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The second step of the synthesis was the preparation of monopropargylated nucleobases. For this, 
uracil, thymine, 6-azauracil and adenine were used as starting materials that were treated with 
propargylbromide in the presence of K2CO3. All reactions were carried out in DMF, as it is an 
excellent solvent for dissolving nucleobases [34] (Scheme 2). The pyrimidine and as-triazine 
derivatives were exclusively alkylated at the N-1 position, (9a–c), and the purine in N-9 position, (9d) 
as confirmed by 
1H-NMR and 
13C-NMR spectra. 
Scheme 2. Preparation of mono-triazolo-carboacyclonucleosides 10a–d. 
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8d: BH = Adenine     9d       10d 
Reagents and conditions: (i) K2CO3, DMF, 24 h; (ii) (1) CuI, Et3N, MW; (2) MeOH/ K2CO3 or NH3/MeOH. Molecules 2012, 17                  
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The terminal triple bonds of propargylated nucleobases were ligated to the azide residue of the 
pseudosugar using copper(I)-catalyzed 1,3-dipolar cycloaddition and Et3N under microwave-assisted 
reaction without solvent [34] (Scheme 2) leading to the 1,4-disubstituted regioisomer in a quantitative 
yield unlike before [22] and a reaction time of one minute (Table 1). We intimately mixed the azide, 
acetylenic derivative and copper(I)-iodide prior to microwave irradiation. This fast and efficient 
method was in all tested cases superior in yield and handling to running the reaction in solution [34]. 
Table 1. Structures of the starting azides, alkynes and corresponding products. 
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Table 1. Cont. 
Entry Azide  Alkyne  Reaction  time  Product 
a Yields(% 
b) 
12c 
N3
AcO
 
N
N
N
O
O
 
 
 
1 min 
N
N
N
O
O N
N
N
HO
N
N
N
HO
 
91 
a All products were characterized by 
1H-NMR, 
13C-NMR, and mass spectrometry; 
b Yields of 
isolated products after deacetylation. 
A common feature of many acyclic nucleoside analogues showing biological activity, including 
HBG, is the presence of a primary alcoholic group. This function and the nucleic acid base are 
essential for their biological activity. For this purpose the deprotected products were obtained in good 
yields by treatment with NH3/methanol or K2CO3/methanol. 
To extend the general applicability of the microwave assisted click reaction for the synthesis of 
triazole acyclonucleosides we included other alkinyl derivatives, as outlined in Scheme 2. Analogously 
to the preparation of N-1-propargylated pyrimidines/as-triazine, the N-1,  N-3-bis-propargylated 
pyrimidines/as-triazines were prepared from N-1-propargylated uracil, thymine and 6-azauracil 
(Scheme 3), (Yields 80–85%). The bis-propargylated pyrimidines/as-triazines were converted into the 
bis-triazole acyclonucleosides using the same reaction conditions in an almost quantitative yield (Table 1). 
Scheme 3. Preparation of bis-triazolo-carboacyclonucleosides 12a–c. 
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Reagents and conditions: (i) K2CO3, DMF, 15 h; (ii) (1) CuI, Et3N, MW; (2) MeOH/ K2CO3 or NH3/MeOH. 
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The structure of all compounds was confirmed on the basis of 
1H-, 
13C-NMR spectra and mass 
spectra. Formation of 1,4-disubstituted triazoles was unequivocally established by the characteristic 
chemical shift values of the triazolyl proton (5-CH) at δ = 7.91–8.10 ppm. The triazole ring formation 
can also be identified from the 13C-spectra with the new signals of the olefinic C-atoms of the 1,2,3-
triazole moiety at (δ (C5) = 122.94–123.39 ppm) and (δ(C4) =141.48–145.44 ppm). 
2.2. Biological Results 
2.2.1. Antibacterial Activity 
The antibacterial activity of all the synthesized compounds 10a–d and 12a–c were examined against 
different Gram-positive Staphylococcus aureus (ATCC 13709 in vivo, ATCC 25923, oxford and 
MRSA  in vivo),  Enterococcus faecalis (ATCC 29212 VanS), Enterococcus faecium (VanA), 
Streptococcus pneumoniae (VanA, ATCC49619, PenR and Blood effect), and Gram-negative 
Haemophilus influenzae (ATCC 31517 MMSA), Escherichia coli (ATCC 25922) Pseudomonas 
aeruginosa (ATCC 27853). We measured the minimum inhibitory concentration (MIC) values, which 
are defined as the lowest concentration of an antimicrobial that visibly inhibits the growth of the 
bacteria after an overnight incubation [37]. Ciprofloxacin and linezolid were used as standard drugs for 
comparison (Table 2). As shown in Table 2, no antibacterial activities against Gram-positive and 
Gram-negative bacteria were noted. All compounds showed antibacterial activity with a range of the 
MICs higher than 64 µg/mL. 
Table 2. Minimum inhibitory concentration (MIC) in μg/mL of medium. 
Strains Phenotype  Cipro  Lin  10a  10b  10c  10d  12a 12b 12c
1 
S. aureus 
Sa1  ATCC13709 
in vivo 0.12  1  >64  >64 >64 >64 >64 >64 >64
2  Sa26  ATCC25923  0.25  1  >64  >64 >64 >64 >64 >64 >64
3  Sa26 + 10% 
Human serum   Serum  effect  0.25  1  >64  >64 >64 >64 >64 >64 >64
4  Sa26 + 50% 
Human serum   Serum  effect  0.5  2  >64  >64 >64 >64 >64 >64 >64
5  Sa4  Oxford  0.12  1  >64  >64 >64 >64 >64 >64 >64
6  Sa2 MRSA,  in vivo 8  1  >64  >64 >64 >64 >64 >64 >64
7  E. faecalis  Ecalis1  ATCC29212 
VanS  0,5  2  >64  >64 >64 >64 >64 >64 >64
8  E. faecium  Ecium1  VanA  16  0.5  >64  >64 >64 >64 >64 >64 >64
9 
S. pneumoniae 
Pn1  ATCC49619  1  1  >64  >64 >64 >64 >64 >64 >64
10  Pn9  PenR  0.5  0.5  >64  >64 >64 >64 >64 >64 >64
11  Pn9+2.5% 
blood  Blood  effect  0.5  0.25  >64  >64 >64 >64 >64 >64 >64
12  H. influenzae  Hi3  ATCC 31517 
MMSA  ≤0.03  16  >64  >64 >64 >64 >64 >64 >64
14  E. coli  Ec1 ATCC25922  ≤0.03  >32  >64  >64 >64 >64 >64 >64 >64
16  P. aeruginosa  Pa1  ATCC  27853  0,25  >32  >64  >64 >64 >64 >64 >64 >64
Cipro: Ciprofloxacin; Lin: Linezolid. Molecules 2012, 17                  
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2.2.2. Antiviral Activity and Cytotoxicity 
Antiviral activities of the synthesized compounds were screened against two types of viruses in 
human epithelial (HeLa) cells for HRV and Human hepatocarcinoma (Huh) cells for HCV. For each 
compound, the 50% and 90% effective concentration (EC50, EC90) and the minimal toxic concentration 
(MTC) or the 50% cytotoxic concentration (CC50) was obtained. None of the compounds exhibited 
specific antiviral activity, which means that they did not inhibit the replication (induction of viral 
cytopathogenicity) of any of the viruses tested. 
3. Experimental 
3.1. General 
NMR spectra were recorded at 250 MHz and 300 MHz (
1H, 
13C) Bruker in (DMSO-d6, CDCl3) 
using TMS as an internal reference. All chemical shifts (δ) are expressed in parts per million (s, 
singlet; d, doublet; t, triplet; and m, multiplet) and coupling constants (J) are given in Hertz;   
T (1,2,3-triazole) and B (heterocyclic base). Mass spectra were obtained by using MALDI-TOF and 
(FAB
+). Reactions were performed in a domestic microwave oven Model AVM510/WP/WH. DMF 
was distilled prior to use and stored over molecular sieves 4A. Precoated Merck Silica Gel 60F-254 
plates were used for thin layer chromatography (TLC) and the spots were detected under UV light  
(254 nm). Column chromatography (CLC) was performed using silica gel (0.063–0.2 mm) Fluka. All 
reagents used were purchased from Aldrich. MICs were determined based on CLSI methodology [37] 
by a 2-fold broth dilution technique in Mueller Hinton (MH, pH 7.4 Biorad). For S.pneumoniae the 
medium was Brain Heart Infusion broth + 4% red blood cell extract. For H. influenzae the medium was 
HTM (Haemophilus Test Medium consisting of MH + 5 g/L yeast extract + hemin 15 mg/L + NAD  
20 mg/L). Overnight cultures were diluted to obtain the final inoculum of 105 cfu/well. Incubation was 
37 °C overnight in ambient air. 4-Bromobutylacetate (6) and 4-azidobutylacetate (7) were prepared as 
described below. 
4-Bromobutylacetate (6). To distilled acetyl bromide (100 mmol, 12.3 g) was added  tetrahydrofuran 
(100 mmol, 7.2 g) dropwise while agitating and cooling with an ice bath. The reaction is fast and 
exothermic. After addition, the reaction is agitated further during 30 min at room temperature and 
afterwards the reaction mixture was distilled under reduced pressure. Boiling Point: 92–93 °C (12 mmHg) 
(96%), 
1H-NMR (CDCl3, δ): 1.6 (m, 4H, CH2CH2); 2.0 (s, 3H, CH3COO); 3.48 (t, 2H, CH2Br); 4.03 (t, 
2H, OCH2). 
4-Azidobutylacetate (7). To a solution of 4-bromobutylacetate (6, 10 mmol, 2 g) in anhydrous DMF 
(60 mL) was added sodium azide (NaN3, 15 mmol, 0.9 g). The mixture was brought up to a 
temperature of 90–95 °C during 4 h. After cooling, the solution was extracted with ether (2 × 50 mL) 
then washed with brine, and dried (MgSO4). After removal of the solvents under reduced pressure, the 
residual oil was purified on a silica gel column with hexane (91%). 
1H-NMR (CDCl3, δ): 1.64 (m, 4H, 
CH2CH2); 2.0 (s, 3H, CH3COO); 3.3 (t, 2H, OCH2); 4.1 (t, 2H, CH2N3). Molecules 2012, 17                  
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3.2. General Procedure for the Synthesis of Monopropargyl Heterocyclic Bases 
The mixture of heterocyclic base (thymine, uracil, 6-azauracil and adenine, 1 mmol), K2CO3 (0.5 mmol) 
and propargyl bromide (1 mmol) in anhydrous DMF (20 mL) was stirred at room temperature during 
24 h. After removal of the solvent under reduced pressure the residue obtained was purified on a silica 
gel column eluted with CH2Cl2 and MeOH (99/1). 
N-1-propargyl-6-azauracil (9c). Yield: 55%. 
1H-NMR (DMSO-d6, δ): 3.91 (t, 1H, CH); 4.45 (d, 2H, 
CH2N); 7.46 (s, 1H, H-5); 11.44 (s, 1H, NH). 
13C-NMR (DMSO-d6, δ): 28.37; 73.11; 77.53; 134.61; 
148.36; 155.41. FAB-MS, m/z calcd for C6H5N3O2 (M+H)
+ 152.04 found,152. 
3.3. General Procedure for the Synthesis of the N-1, N-3-Bis-propargylpyrimidines/as-Triazines 
The mixture of the heterocyclic base (N-1-propargyluracil,  N-1-propargylthymine, and N-1-
propargyl-6-azauracil, 1 mmol), K2CO3 (0.5 mmol) and propargylbromide (1.1 mmol) in anhydrous 
DMF (20 mL) was stirred at room temperature during 15 h. After removal of the solvent under reduced 
pressure and purification on silica gel column chromatography, we obtained the desired pure product. 
N-1,N-3-dipropargyl-6-azauracil (11c). Yield: 85%. 
1H-NMR (DMSO-d6, δ): 2.98 (t, 1H, CH); 3.44 (t, 
1H, CH); 4.48 (d, 2H, CH2N); 4.67 (d, 2H, CH2N); 7.58 (s, 1H, H-5). 
13C-NMR (DMSO-d6, δ): 29.38; 
39.40; 73.50; 75.43; 77.36; 77.64; 134.81; 147.11; 154.90. FAB-MS, m/z calcd for C8H8N2O2 (M+H)
+ 
190.05 found, 190. 
3.4. General Procedure for the Synthesis of the Triazole acyclonucleoside Derivatives 
The mixture of alkylazide (5 mmol), Et3N (1 mmol), N-propargylbase (1 mmol) and CuI (0.1 mmol) 
was irradiated in the microwave oven at power level (300 W) for 1 min without solvent. K2CO3  
(2 mmol) in methanol (10 mL) was added directly to reaction mixture. The mixture was stirred for 
additional 3 h at room temperature (or in 30 mL of methanol saturated with ammonia at 0 °C during 24 h). 
When TLC analysis showed no starting material, solvent was removed under reduced pressure, and the 
residue was purified on silica gel eluting with dichloromethane and methanol. 
1-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]uracil (10a). Yield: 91%. 
1H-NMR (DMSO-d6, 
δ): 1.44–1.29 (m, 2H, CH2); 1.90–1.75 (m, 2H, CH2); 3.45–3.37 (m, 2H, OCH2); 4.35 (t, 2H, CH2-T,  
J = 7.13); 4.47 (t, 1H, OH, J = 4.62); 4.94 (s, 2H, T-CH2-B); 5.60 (d, 1H, H-5, J = 7.85 Hz); 7.75 (d, 
1H, H-6, J = 7.87 Hz); 8.08 [s, 1H, H-5(triazole)]; 11.31 (s, 1H, NH). 
13C-NMR (DMSO-d6, δ): 26.56; 
29.24; 42.39; 49.34; 59.98; 101.23; 123.36; 142.23; 145.44; 150.72; 163.65. (MALDI-TOF-MS) m/z 
calcd for C11H15N5O3 265.12, found, 266.87. 
1-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]thymine ( 10b). Yield: 92%. 
1H-NMR 
(DMSO-d6, δ): 1.44–1.30 (m, 2H, CH2); 1.76 (s, 3H, CH3); 1.85 (m, 2H, CH2); 3.44–3.36 (m, 2H, 
OCH2); 4.34 (t, 2H, CH2-T, J = 7.15 Hz); 4.47 (t, 1H, OH, J = 5.10 Hz); 4.90 (s, 2H, T-CH2-B); 7.62 
(s, 1H, H-6), 8.07 [s, 1H, H-5(triazole)]; 11.30 (s, 1H, NH). 
13C-NMR (DMSO-d6, δ): 11.91; 26.56; Molecules 2012, 17                  
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29.25; 42.23; 49.33; 59.98; 108.83; 123.32; 141.11; 142.40; 150.69; 164.24. (MALDI-TOF-MS) m/z 
calcd for C12H17N5O3 279.13, found, 279.07. 
1-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]-6-azauracil ( 10c). Yield: 90%. 
1H-NMR 
(DMSO-d6, δ): 1.37 (m, 2H, CH2); 1.90–1.73 (m, 2H, CH2); 3.43–3.37 (m, 2H, OCH2); 4.32 (t, 2H, CH2-T, 
J = 7.16); 4.47 (s, 1H, OH); 4.98 (s, 2H, T-CH2-B); 7.56 (s, 1H, H-5); 8.02 [s, 1H, H-5(triazole)]; 
12.64 (s, 1H, NH). 
13C-NMR (DMSO-d6,  δ): 26.55; 29.25; 34.52; 49.27; 59.99; 123.32; 134.75; 
141.48; 148.86; 155.89. (MALDI-TOF-MS) m/z calcd for C10H14N6O3 266.11, found, 266.64. 
1-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]adenine ( 10d). Yield: 89%. 
1H-NMR 
(DMSO-d6, δ): 1.35 (m, 2H, CH2); 1.79 (m, 2H, CH2); 3.39 (m, 2H, OCH2); 3,47 (s, 1H, OH); 4.33 (t, 
2H, T, J = 7.13 Hz); 5.44 (s, 2H, T-CH2-B); 7.24 (s, 2H, NH2); 8.10 [s, 1H, H-5(triazole)]; 8.15 and 
8.20 (s, 2H, H-2 and H-8). 
13C-NMR (DMSO-d6,  δ): 26.55; 29.21; 38.02; 49.33; 59.95; 118.57; 
123.39; 140.61; 142.42; 149.29; 155.96; 152.55. (MALDI-TOF-MS) m/z calcd for C12H16N8O 288.14, 
found, 288.11. 
1,3-bis-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]uracil ( 12a). Yield: 90%. 
1H-NMR 
(DMSO-d6, δ): 1.44–1.29 [m, 4H, 2 × (CH2)]; 1.90–1.73 [m, 4H, 2 × (CH2)]; 3.40 [m, 4H, 2 × (OCH2)]; 
4.32 [m, 4H, 2 × (CH2)]; 4.47 [s, 2H, 2 × (OH)]; 5.02 [s, 4H, 2 × (T-CH2-B)]; 5.78 (d, 1H, H-5,  
J = 7.89 Hz); 7.84 (d, 1H, H-6, J = 7.91 Hz); 7.92 [s, 1H, H-5(triazole)]; 8.10 [s, 1H, H-5(triazole)]. 
13C-NMR (DMSO-d6, δ): 2 × (C) 26.56; 2 × (C) 29.24; 35.84; 43.59; 49.22; 49.36; 2 × (C) 59.99; 
100.50; 123.15; 123.52; 141.98; 142.48; 144.21; 150.74; 161.99. (MALDI-TOF-MS) m/z calcd for 
C18H26N8O4 418.21, found, 418.46  
1,3-bis-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]thymine ( 12b). Yield: 92%. 
1H-NMR 
(DMSO-d6, δ): 1.45–1.30 [m, 4H, 2 × (CH2)]; 1.90–1.75 [m, 7H, 2 × (CH2) and CH3]; 3.40 [m, 4H,  
2 × (OCH2)]; 4.32 [m, 4H, 2 × (CH2-T)]; 4.49 [s, 2H, 2 × (OH)]; 4.98 (s, 2H, T-CH2-B); 5.05 (s, 2H, 
T-CH2-B); 5.74 (s, 1H, H-6); 7.91 [s, 1H, H-5(triazole)]; 8.09 [s, 1H, H-5(triazole)]. 
13C-NMR (DMSO-d6, 
δ): 12.56; 2 × (C) 26.57; 2 × (C) 29.26; 36.10; 43.43; 49.21; 49.35; 2 × (C) 59.98; 108.09; 123.16; 
123.47; 140.05; 142.15; 142.56; 150.58; 162.73. (MALDI-TOF-MS) m/z calcd for C19H28N8O4 432.22, 
found, 432.64. 
1,3-bis-[[1-[(4-Hydroxybutyl)methyl]-1,2,3-triazol-4-yl]methyl]-6-azauracil ( 12c). Yield: 91%. 
1H-
NMR (DMSO-d6, δ): 1.36 [m, 4H, 2 × (CH2)]; 1.81 [m, 4H, 2 × (CH2)]; 3.37 [m, 4H, 2 × (OCH2)], 
4.32 [m, 4H, 2 × (CH2-T)]; 4.43 (s, 2H, 2 × (OH); 4.80 (s, 2H, T-CH2-B); 5.06 (s, 2H, T-CH2-B); 7.14 
(s, 1H, H-5); 7.91 [s, 1H, H-5(triazole)]; 7.98 [s, 1H, H-5(triazole)]. 
13C-NMR (DMSO-d6, δ): 2 × (C) 
26.5; 2 × (C) 29.27; 35.71; 36.65; 2 × (C) 49.23; 2 × (C) 59.95; 122.71; 2 × (C) 122.94; 2 × (C) 141.89; 
145.40; 155.46. (MALDI-TOF-MS) m/z calcd for C17H25N9O4 419.20, found, 419.17. 
4. Conclusions 
A series of triazole carboacyclonucleosides with various nucleobase moieties appended on the 
triazole were synthesized efficiently using a convenient one-step click azide-alkyne cycloaddition 
reaction under solvent-free microwave irradiation. All compounds synthesized were evaluated for their Molecules 2012, 17                  
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antibacterial and antiviral activities but none exhibited specific activity so far. Further applications of 
the click azide-alkyne cycloaddition process are currently under investigation and will be reported in 
due course. 
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